Abstract

REMDESIVIR AFFECT ON COVID-19

Prof. Ashwini D. Pagare, Prof. Ganesh B. Ahire, *Rohit B. Goyekar, Samadhan N.

.

Abstract

Pandemic Covid-19, an infectious disease brought on by SARS COV- 2, starts in 2020. The respiratory system is the primary target of the illness. The Chinese city of Wuhan was the source of the first instance of respiratory tract sickness. Researchers from all around the world are conducting a variety of studies in an effort to create a medication that is both successful at treating and preventing disease. There isn't currently a prescribed treatment plan in place. Russian scientists created the SPUTNIK-V vaccine, which is meant to protect against SARS COV-2. A number of antiviral and anti-inflammatory drugs were included in the treatment plan. On May 1, 2020, the FDA approved Remdisivir's usage as an emergency use authorization to treat Covid-19. Method: The review paper was prepared by referring research and review article from various sites like PubChem, Pubmed, Google Scholar, European Medical Agency; Science Direct. Etc. Observation: Remdesivir is a drug with broad antiviral activity. It is Adenosine Triphsosphate Analogue which was developed for potential treatment of Ebola virus. Remedisivir is also active against Nipah respiratory Syncytialvirus. MERS-COV. In various studies the drug has shown clinical improvement in patient as well as optimal safety profile was observed. Several studies are still continuing to picture out the efficiency and safety of Remedisivir in Covid-19 patients.

Keywords: Oseltamivir, Hydroxychloroquine, diastereomer monophosphoramidate, ebolavirus, Clavulanate.